Callan Family Office LLC acquired a new position in shares of GSK plc (NYSE:GSK - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 57,712 shares of the pharmaceutical company's stock, valued at approximately $1,952,000.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Indiana Trust & Investment Management Co increased its position in GSK by 200.0% during the 4th quarter. Indiana Trust & Investment Management Co now owns 750 shares of the pharmaceutical company's stock valued at $25,000 after buying an additional 500 shares in the last quarter. Crews Bank & Trust purchased a new position in shares of GSK in the 4th quarter worth about $26,000. ST Germain D J Co. Inc. grew its position in GSK by 195.5% during the 4th quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company's stock valued at $27,000 after purchasing an additional 522 shares during the last quarter. Sunbelt Securities Inc. grew its position in GSK by 73.8% during the 3rd quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company's stock valued at $29,000 after purchasing an additional 302 shares during the last quarter. Finally, Sierra Ocean LLC bought a new stake in GSK during the 4th quarter valued at about $32,000. Hedge funds and other institutional investors own 15.74% of the company's stock.
GSK Stock Performance
Shares of GSK traded up $0.62 during trading hours on Monday, hitting $40.67. The stock had a trading volume of 2,071,538 shares, compared to its average volume of 4,231,275. GSK plc has a 12 month low of $31.72 and a 12 month high of $45.93. The stock has a fifty day moving average price of $35.47 and a 200 day moving average price of $37.14. The company has a debt-to-equity ratio of 1.12, a current ratio of 0.78 and a quick ratio of 0.52. The firm has a market capitalization of $84.29 billion, a PE ratio of 25.56, a PEG ratio of 1.12 and a beta of 0.58.
GSK (NYSE:GSK - Get Free Report) last released its quarterly earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 EPS for the quarter, beating the consensus estimate of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%. Analysts anticipate that GSK plc will post 4.14 EPS for the current year.
GSK Increases Dividend
The firm also recently declared a quarterly dividend, which will be paid on Thursday, April 10th. Stockholders of record on Friday, February 21st will be paid a dividend of $0.3932 per share. This represents a $1.57 annualized dividend and a dividend yield of 3.87%. The ex-dividend date is Friday, February 21st. This is a boost from GSK's previous quarterly dividend of $0.39. GSK's dividend payout ratio (DPR) is currently 98.74%.
Wall Street Analyst Weigh In
GSK has been the topic of several analyst reports. Deutsche Bank Aktiengesellschaft downgraded shares of GSK from a "buy" rating to a "hold" rating in a research note on Friday, November 15th. Morgan Stanley started coverage on GSK in a research note on Wednesday, February 12th. They set an "equal weight" rating on the stock. Jefferies Financial Group cut GSK from a "buy" rating to a "hold" rating and decreased their price target for the stock from $53.00 to $39.50 in a research note on Tuesday, November 12th. Finally, StockNews.com raised GSK from a "buy" rating to a "strong-buy" rating in a research report on Friday, February 7th. Seven research analysts have rated the stock with a hold rating and four have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, GSK presently has an average rating of "Moderate Buy" and an average target price of $43.25.
Read Our Latest Analysis on GSK
GSK Profile
(
Free Report)
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.
See Also
Before you consider GSK, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GSK wasn't on the list.
While GSK currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
